2-Chlorodeoxyadenosine in the Treatment of Hairy Cell Leukemia

References

• Bouroncle B A, Wiseman B K, Doan C A. Leukemic reticuloendo-theliosis. Blood 1958; 13: 609–630
   PubMed Web of Science ®Google Scholar
• Flandrin G, Sigaux F, Sebahoun G, et al. Hairy cell leukemia: Clinical presentation and follow-up of 211 patients. Semin Oncol 1984; 11: 458
   PubMed Web of Science ®Google Scholar
• Yam L T, Li C Y, Lam K W. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheli-osis. N Engl J Med 1971; 284: 357–360
   PubMed Web of Science ®Google Scholar
• Golomb H M, Catovsky D, Golde D W. Hairy cell leukemia: A clinical review of 71 cases. Ann Intern Med 1978; 89: 677–683
   PubMed Web of Science ®Google Scholar
• Mintz U, Golomb H M. Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res 1979; 39: 2366–2370
   PubMed Web of Science ®Google Scholar
• Jansen J, Hermans J. Splenectomy in hairy cell leukemia: A retrospective multicenter analysis. Cancer 1981; 47: 2066–2076
   PubMed Web of Science ®Google Scholar
• Golomb H M. Progress report on chlorambucil therapy in post-splenectomy patients with progressive hairy cell leukemia. Blood 1981; 57: 464–467
   PubMed Web of Science ®Google Scholar
• Blum S F. Lithium in hairy cell leukemia. N Engl J Med 1983; 303: 464–465
   Google Scholar
• Lusch C J, Ramsey H E, Katayama I. Leukemic reticuloendotheliosis: Report of a case with peripheral blood remission on androgen therapy. Cancer 1978; 41: 1964–1966
   PubMed Web of Science ®Google Scholar
• Stewart D J, Benjamin R S, McCredie K B, et al. The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis). Blood 1979; 54: 298–303
   PubMed Web of Science ®Google Scholar
• Quesada J R, Reuben J, Manning J T, et al. Alpha-interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984; 310: 15–18
   PubMed Web of Science ®Google Scholar
• Spiers A SD, Parekh S J. Pentostatin (2′-deoxycoformycin, DCF) is active in hairy cell leukemia (HCL) (abstract). Blood 1983; 62: 208
   Google Scholar
• Spiers A SD, Parekh S J, Bishop M B. Hairy-cell leukemia: Induction of complete remission with pentostatin (2′-deoxyco-formycin). J Clin Oncol 1984; 2: 1336–1342
   PubMed Web of Science ®Google Scholar
• Golomb H M, Fefer A, Golde D W, et al. Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon alfa-2b. Semin Oncol 1988; 15(Suppl 5)7–9
   PubMed Web of Science ®Google Scholar
• Spies A SD, Moore D, Cassileth P A, et al. Remissions in hairy cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987; 316: 825–830
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, Cheson B D, Leyland-Jones B, et al. Deoxyco-formycin: An active new drug for indolent lymphomas and hairy cell leukemia. Oncology 1988; 2: 17–22
   PubMedGoogle Scholar
• Tamura A, Asano T, Sano K. Correlation between rCBF and histological changes following temporary middle cerebral artery occlusion. Stroke 1980; 11: 487–493
   PubMed Web of Science ®Google Scholar
• Johnston J B, Glazer R I, Pugh L, et al. The treatment of hairy-cell leukemia with 2′-deoxycoformycin. Br J Haematol 1986; 63: 525–534
   PubMed Web of Science ®Google Scholar
• Piro L D, Carrera C J, Carson D A, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Carson D A, Carrera C J. Immunodeficiency secondary to adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. Semin Hematol 1990; 27: 260–269
   PubMed Web of Science ®Google Scholar
• Carson D A, Kaye J, Wasson D B, et al. Deoxycytidine kinase mediated toxicity of deoxyadenosine analogs towards malignant human lymphoblasts in vivo. Proc Natl Acad Sci USA 1980; 77: 6865–6869
   PubMed Web of Science ®Google Scholar
• Carson D A, Wasson D B, Beutler E. Antileukemia and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1981; 81: 2232–2236
   Web of Science ®Google Scholar
• Carson D A, Wasson D B, Beutler E. Anti-leukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 1984; 81: 2232–2236
   PubMed Web of Science ®Google Scholar
• Carrera C J, Terai C, Piro L, et al. 2-CdA chemotherapy triggers programmed cell death in normal and malignant lymphocytes. J Purine Pyrimidine Res 1991; 2(Suppl 1)38
   Google Scholar
• Seto S, Carrera C J, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Carson D A, Wasson D B, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62(4)737–743
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Wasson D B, Saven A, et al. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemo-therapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597–601
   PubMed Web of Science ®Google Scholar
• Beutler E, Piro L D, Saven A, et al. 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleotide. Leukemia Lymphoma 1991; 5: 1–8
   PubMed Web of Science ®Google Scholar
• Kay A C, Saven A, Carrera C J, et al. 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Saven A, Carrera C J, Carson D A, et al. 2-Chlorode-oxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80: 587–592
   PubMed Web of Science ®Google Scholar
• Piro L D, Miller W E, Carrera C J, et al. Hairy-cell leukemia (letter). N Engl J Med 1987; 317: 901
   PubMedGoogle Scholar
• Piro L D, Carrera C J, Carson D A, et al. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Piro L D, Saven A, Ellison D, et al. Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL) (abstract). Proc Am Soc Clin Oncol 1992; 11: 846
   Google Scholar
• Kraut E H, Neff J C, Bouroncle B A, et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8: 848–855
   PubMed Web of Science ®Google Scholar
• Urba W J, Baseler M W, Kopp W C, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989; 73: 38–46
   PubMed Web of Science ®Google Scholar
• Carrera C J, Piro L D, Saven A, et al. Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia. Blood 1990; 76(Suppl l)260a
   Google Scholar
• Estey E M, Kurzrock R, Kantarjian H M, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882–887
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chIoro-2′-deoxy-adenosine (CdA): Relation to opportunistic infections. Blood 1992; 79: 888–894
   PubMed Web of Science ®Google Scholar
• Hoffman M, Rai K, Sawitsky A, et al. 2-Chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (abstract). Blood 1991; 78(Suppl l)454a
   Google Scholar
• Tallman M, Hakimian D, Variakojis D, et al. 2-Chlorode-oxyadenosine (2-CdA) in the treatment of hairy cell leukemia (HCL) (abstract). Blood 1991; 78(Suppl l)34a
   Google Scholar
• Lauria F, Benfenati D, Zinzani P L, et al. 2-Chlorode-oxyadenosine in the treatment of hairy cell leukemia patients relapsed after a-interferon (abstract). Blood 1991; 78(Suppl 1)34a
   Google Scholar